Patricia Martín-Romano
Institut Gustave Roussy(FR)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research, Epigenetics and DNA Methylation, CAR-T cell therapy research
Most-Cited Works
- → The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology(2022)125 cited
- → Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study(2019)104 cited
- → Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.(2022)66 cited
- → The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study(2020)59 cited
- → Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics(2021)57 cited
- → Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)(2020)56 cited
- → Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation(2022)54 cited
- → Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.(2021)54 cited
- → Clinical activity of CC‐90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies(2022)46 cited
- → Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma(2020)43 cited